DA-1229 — Competitive Intelligence Brief

DA-1229 (DA-1229) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: DPP-4 inhibitor. Area: Diabetes.

phase 2 DPP-4 inhibitor DPP-4 (Dipeptidyl peptidase-4) Diabetes Small molecule

Target snapshot

DA-1229 (DA-1229) — Dong-A ST Co., Ltd.. DA-1229 is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases levels of incretin hormones to improve blood glucose control in type 2 diabetes.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
DA-1229 TARGET	DA-1229	Dong-A ST Co., Ltd.	phase 2	DPP-4 inhibitor	DPP-4 (Dipeptidyl peptidase-4)
oral hypoglycemic agents	oral hypoglycemic agents	Queen Elizabeth II Health Sciences Centre	marketed	Oral hypoglycemic agents (multiple classes: sulfonylureas, meglitinides, biguanides, thiazolidinediones, DPP-4 inhibitors, GLP-1 agonists, SGLT2 inhibitors)
Sitagliptin combined with metformin	Sitagliptin combined with metformin	Sun Yat-sen University	marketed	DPP-4 inhibitor combined with biguanide	DPP-4 enzyme; metformin acts on multiple targets including mitochondrial complex I
DPP-4 inhibitor + metformin group	DPP-4 inhibitor + metformin group	Beni-Suef University	marketed	DPP-4 inhibitor + biguanide combination	DPP-4 enzyme; metformin acts on multiple targets including mitochondrial glycerophosphate dehydrogenase
alogliptin and actoplus met	alogliptin and actoplus met	The Fourth Affiliated Hospital of Zhejiang University School of Medicine	marketed	DPP-4 inhibitor + biguanide combination	DPP-4 enzyme; metformin acts on multiple targets including mitochondrial glycerophosphate dehydrogenase
exenatide and sitagliptin	exenatide and sitagliptin	AstraZeneca	marketed	GLP-1 receptor agonist and DPP-4 inhibitor combination	GLP-1 receptor (exenatide); DPP-4 (sitagliptin)
Sitagliptin (Januvia)	Sitagliptin (Januvia)	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	marketed	DPP-4 inhibitor	DPP-4 (dipeptidyl peptidase-4)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (DPP-4 inhibitor class)

1. Merck Sharp & Dohme LLC · 5 drugs in this class
2. Daewoong Pharmaceutical Co. LTD. · 4 drugs in this class
3. AstraZeneca · 4 drugs in this class
4. LG Life Sciences · 2 drugs in this class
5. Tanabe Pharma Corporation · 2 drugs in this class
6. Ain Shams University · 2 drugs in this class
7. Ono Pharmaceutical Co. Ltd · 2 drugs in this class
8. Cinnagen · 1 drug in this class
9. GRADE Study Group · 1 drug in this class
10. CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · 1 drug in this class